Abstract:Taxol-based chemotherapy is widely used as the first-line treatment for non-small cell lung cancer (NSCLC), however, the subsequent development of taxol-resistance is a major concern and challenge, resulting in tumor relapse and poor prognosis. Given the complex nature of taxol-resistance, we further delved into its mechanisms and demonstrated that CYP1B1 was associated to taxol response in taxol-resistant A549/Taxol cells. Compared to its parent A549 counterpart, A549/Taxol presented much higher level of CYP1B1, which was paralleled by increased aryl hydrocarbon receptor (AhR) expressions likely due to the long term taxol exposure and thereby allowed a subsequent up-regulation of CYP1B1. Inhibition of CYP1B1 by TMS [(E)-2,3',4,5'-tetramethoxystilbene], the specific CYP1B1 inhibitor, remarkably enhanced the sensitivity of A549/Taxol to taxol. Moreover, pre-incubation of taxol with human recombinant CYP1B1 did not affect drug toxicity in A549 cells, precluding the possibility of drug resistance ascribed to CYP1B1 due to directly inactivating taxol. Indeed, CYP1B1 is responsible for bio-transforming estrogen (E2) into the carcinogenetic metabolite that would inhibit microtubule stabilization induced by taxol and thereby compromising treatment efficacy. Remarkably, our data revealed potent CYP1B1 inhibition efficacy of 4-hydroxyemodin (HEM) as reflected by both molecular docking simulations and EROD assay, which posed HEM the advantage of breaking the vicious circle between E2 and CYP1B1, not only favoring to overcome taxol-resistance, but also offering long term benefit via circumventing carcinogenesis and tumor progression induced by E2. In addition to CYP1B1 inhibition, HEM notably inhibited P-gp activity and expression, a common feature of drug resistance, as well as significantly inactivated AKT/ERK pathways that contributed to the cell proliferation, migration, and drug resistance. Thus, HEM may act in concert to overcome taxol-resistance through comprehensive targeting three considered arms of drug-resistance mechanisms. Moreover, HEM profoundly resisted E2-stimulated cell migration in both A549 and A549/Taxol cells, a primary reason for tumor patients' mortality, as well as inflicted selective injury to A549/Taxol cells rather than normal lung cells, supporting HEM to be a promising agent for overcoming taxol-resistance in A549 cells.

The characteristics of Hep-2 cell with multiple drug resistance induced by Taxol.

The Building of Multiple Drug Resistant Human Laryngeal Cancer Cell Line and Its Characteristics

Study on Taxol in Inhibiting Human Leukemia Cell Proliferation and Inducing Apoptosis

Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line

Establishment and biological characteristics of Taxol-induced drug resistant human lung adenocarcinoma cell line

Characterization of TAXOL-resistance Ovarian Cancer Cell Lines Induced by Different Administrations Approaches

Establishment and characterization of a Taxol induced drug-resistant human lung adenocarcinoma cell subline

Establishment of a Drug-Resistant Human Cervical Cancer Cell Line and Research on Its Drug-Resistance

Establishment of Paclitaxel-Resistant Breast Cancer Cell Line and Nude Mice Models, and Underlying Multidrug Resistance Mechanisms in Vitro and in Vivo.

Systematic profiling of Taxol resistance and sensitivity to tubulin missence mutations at molecular and cellular levels

[The Effect of MDR1 (P-Gp) and ABCG2 on the Drug Resistance in Hep 2 Cells].

MDR1/P-gp and VEGF Synergistically Enhance the Invasion of Hep-2 Cells with Multidrug Resistance Induced by Taxol

Establishment of a docetaxel-induced human breast carcinoma drug-resistant cell line BT549/docetaxel and the mRNA expression of adenosine triphosphate binding cassette transporter G2, adenosine triphosphate binding cassette subfamily B member 1, multidrug

The Role of CYP1B1 in Paclitaxel Resistance in Breast Cancer

Establishment of a Docetaxel-Induced Human Breast Carcinoma Drug-Resistant Cell Line MCF7/docetaxel and Its Biological Characteristics

Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin

Study on Biological Characteristics and Mechanism of Paclitaxel Induced Drug Resistance in Endometrial Carcinoma Cells

Experimental Study of Radiosensitization Effect of Taxol on Laryngeal Squamous Carcinoma Hep-2 Cell Lines

Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7

Cell-cycle Synchronization Reverses Taxol Resistance of Human Ovarian Cancer Cell Lines